Acceleron Pharma discontinues development of muscular dystrophy drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

The clinical-stage biopharmaceutical company Acceleron Pharma Inc. has announced the discontinuation of the development of drug for facioscapulohumeral muscular dystrophy (FSHD), ACE-083. Further clinical trials will not be conducted in this arena as the drug could not achieve statistically significant improvements in functional endpoints relative to placebo in a Phase II trial.

The drug indicated an increase in mean total muscle volume but failed to convert to statistically significant improvements in functional tests. As expected Acceleron Pharma was disappointed with the way things had gone as it always stated that ACE-083 would prove to be an important new therapy for patients with FSHD, a genetic muscular disorder where muscles of the face, shoulder blades and upper arms are among the most affected.

Habib Dable, President and chief executive officer of Acceleron expressed his disappointment and said that the data showed no evidence to support further development of ACE-083. The company, however, is looking forward to the first quarter of the next year as it is expecting top-line results from the placebo-controlled Phase II trial of ACE-083 in patients having Charcot-Marie-Tooth disease which is a neuromuscular disorder of different pathophysiology.

Latest stories

Related stories

PDUFA Crucial for Biopharmaceutical Innovation in the US

The United States happens to lead the world when...

Fangzhou Inc. at PHARMCHINA Showcases AI-Powered Healthcare

The 4th Annual "Internet + Pharma" Service Innovation Conference,...

The Evolution of Self-Care: Where Vitauthority Fits in the Wellness Era

Over the past few decades, the concept of self-care...

Piramal Pharma Expands Lexington Sterile Injectables Plant

Piramal Pharma has started work on the expansion of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back